BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8039602)

  • 1. Aldose reductase catalysis and crystallography. Insights from recent advances in enzyme structure and function.
    Petrash JM; Tarle I; Wilson DK; Quiocho FA
    Diabetes; 1994 Aug; 43(8):955-9. PubMed ID: 8039602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residues affecting the catalysis and inhibition of rat lens aldose reductase.
    Carper DA; Hohman TC; Old SE
    Biochim Biophys Acta; 1995 Jan; 1246(1):67-73. PubMed ID: 7811733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel NADPH-binding domain revealed by the crystal structure of aldose reductase.
    Rondeau JM; Tête-Favier F; Podjarny A; Reymann JM; Barth P; Biellmann JF; Moras D
    Nature; 1992 Jan; 355(6359):469-72. PubMed ID: 1734286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of porcine aldehyde reductase holoenzyme.
    el-Kabbani O; Judge K; Ginell SL; Myles DA; DeLucas LJ; Flynn TG
    Nat Struct Biol; 1995 Aug; 2(8):687-92. PubMed ID: 7552731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
    Sotriffer CA; Krämer O; Klebe G
    Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Search of Differential Inhibitors of Aldose Reductase.
    Balestri F; Moschini R; Mura U; Cappiello M; Del Corso A
    Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
    El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
    Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications.
    Vander Jagt DL; Hassebrook RK; Hunsaker LA; Brown WM; Royer RE
    Chem Biol Interact; 2001 Jan; 130-132(1-3):549-62. PubMed ID: 11306074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites.
    El-Kabbani O; Podjarny A
    Cell Mol Life Sci; 2007 Aug; 64(15):1970-8. PubMed ID: 17497245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro expression of rat lens aldose reductase in Escherichia coli.
    Old SE; Sato S; Kador PF; Carper DA
    Proc Natl Acad Sci U S A; 1990 Jul; 87(13):4942-5. PubMed ID: 2114645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
    ElGamal H; Munusamy S
    Protein Pept Lett; 2017; 24(1):71-77. PubMed ID: 27894247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
    Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
    Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aldose reductase in the polyol pathway: a potential target for the therapeutic intervention of diabetic complications].
    Nishimura-Yabe C
    Nihon Yakurigaku Zasshi; 1998 Mar; 111(3):137-45. PubMed ID: 9583077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel insights into the structural requirements for the design of selective and specific aldose reductase inhibitors.
    Kumar H; Shah A; Sobhia ME
    J Mol Model; 2012 May; 18(5):1791-9. PubMed ID: 21833829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All in the family: aldose reductase and closely related aldo-keto reductases.
    Petrash JM
    Cell Mol Life Sci; 2004 Apr; 61(7-8):737-49. PubMed ID: 15094999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose Reductase: a cause and a potential target for the treatment of diabetic complications.
    Thakur S; Gupta SK; Ali V; Singh P; Verma M
    Arch Pharm Res; 2021 Jul; 44(7):655-667. PubMed ID: 34279787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose 6-phosphate.
    Harrison DH; Bohren KM; Ringe D; Petsko GA; Gabbay KH
    Biochemistry; 1994 Mar; 33(8):2011-20. PubMed ID: 8117658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From a dull enzyme to something else: facts and perspectives regarding aldose reductase.
    Del Corso A; Cappiello M; Mura U
    Curr Med Chem; 2008; 15(15):1452-61. PubMed ID: 18537622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The structure of Apo R268A human aldose reductase: hinges and latches that control the kinetic mechanism.
    Bohren KM; Brownlee JM; Milne AC; Gabbay KH; Harrison DH
    Biochim Biophys Acta; 2005 May; 1748(2):201-12. PubMed ID: 15769597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The crystal structure of the aldose reductase.NADPH binary complex.
    Borhani DW; Harter TM; Petrash JM
    J Biol Chem; 1992 Dec; 267(34):24841-7. PubMed ID: 1447221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.